@article{ATM33362,
author = {Shuai Lin and Jun Shen and Wanjun Zhao and Xiaofei Wang and Xiaoqing Wang and Jingqiang Zhu},
title = {Evaluating the effectiveness of targeted therapies for thyroid carcinoma: an updated meta-analysis},
journal = {Annals of Translational Medicine},
volume = {7},
number = {24},
year = {2019},
keywords = {},
abstract = {Background: At present, most of the targeted therapies for thyroid carcinoma are in the clinical trial stage, and there is still no strong evidence to confirm their clinical effect. The aim of this meta-analysis was to evaluate the outcome of targeted therapies and provide quantitative evidence.
Method: Ovid, PubMed, EMBAS, ClinicalTrails.gov, and Cochrane Library electronic databases were searched until September 1, 2019. Randomized controlled studies (RCTs) studies that compared the treatment of thyroid carcinoma with the targeted therapies of utility and complications were analyzed.
Results: The study included 5 studies with a total of 1,615 patients, with 991 cases in the drug group and 624 cases in the placebo group. The meta-analysis indicated that compared with the placebo group, the progression-free survival (PFS) rate of the drug group was significantly improved. The PFS of the drug group was 10.8 to 30.5 months, compared with 4 to 19.3 months for the placebo group (6 months PFS: OR =3.23, 95% CI: 2.57 to 4.05, P},
issn = {2305-5847}, url = {https://atm.amegroups.org/article/view/33362}
}